RvD2 has shown anti-inflammatory effects in experimental models of colitis by reducing neutrophil infiltration and activation, enhancing macrophage-mediated phagocytosis and clearance, decreasing body weight loss, and lowering histological colitis scores and colon shortening—both well-established markers of experimental colitis—while also upregulating the gene expression of the anti-inflammatory cytokine IL-10 [14,15,16]. Here, IL10 is linked to colitis.